OP0186 EFFICACY AND SAFETY OF RILZABRUTINIB, AN ORAL BRUTON'S TYROSINE KINASE INHIBITOR, IN PATIENTS WITH IgG4-RELATED DISEASE: RESULTS FROM A 52-WEEK, PHASE 2, OPEN-LABEL, PROOF-OF-CONCEPT STUDY | Publicación